FI945194A - Kompleksointiaineita ja kohdistavia immunoreagensseja - Google Patents
Kompleksointiaineita ja kohdistavia immunoreagensseja Download PDFInfo
- Publication number
- FI945194A FI945194A FI945194A FI945194A FI945194A FI 945194 A FI945194 A FI 945194A FI 945194 A FI945194 A FI 945194A FI 945194 A FI945194 A FI 945194A FI 945194 A FI945194 A FI 945194A
- Authority
- FI
- Finland
- Prior art keywords
- reactive group
- protein reactive
- alkoxy
- alkyl
- represents hydrogen
- Prior art date
Links
- 230000008685 targeting Effects 0.000 title abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 108090000623 proteins and genes Chemical group 0.000 abstract 8
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- -1 alkylformamido Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 239000008139 complexing agent Substances 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 150000005041 phenanthrolines Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 230000002285 radioactive effect Effects 0.000 abstract 2
- LOAPQPIRTYQPTA-UHFFFAOYSA-N 2-(carboxymethylamino)prop-2-enoic acid Chemical compound OC(=O)CNC(=C)C(O)=O LOAPQPIRTYQPTA-UHFFFAOYSA-N 0.000 abstract 1
- QQQMJWSOHKTWDZ-UHFFFAOYSA-N 2-[amino(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(N)CC(O)=O QQQMJWSOHKTWDZ-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 238000002059 diagnostic imaging Methods 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1992/003858 WO1993021957A1 (en) | 1992-05-07 | 1992-05-07 | Complexing agents and targeting immunoreagents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI945194A0 FI945194A0 (fi) | 1994-11-04 |
| FI945194A true FI945194A (fi) | 1995-01-04 |
Family
ID=22231055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI945194A FI945194A (fi) | 1992-05-07 | 1994-11-04 | Kompleksointiaineita ja kohdistavia immunoreagensseja |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0639083B1 (ja) |
| JP (1) | JP3358141B2 (ja) |
| KR (1) | KR950701229A (ja) |
| AT (1) | ATE203168T1 (ja) |
| AU (1) | AU672951B2 (ja) |
| BR (1) | BR9207126A (ja) |
| CA (1) | CA2135059A1 (ja) |
| DE (1) | DE69231952T2 (ja) |
| FI (1) | FI945194A (ja) |
| NO (1) | NO944182L (ja) |
| RU (1) | RU2122431C1 (ja) |
| WO (1) | WO1993021957A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5480970A (en) * | 1993-12-22 | 1996-01-02 | Resolution Pharmaceuticals | Metal chelators |
| US5569745A (en) * | 1994-02-25 | 1996-10-29 | Resolution Pharmaceuticals Inc. | Peptide-Chelator conjugates |
| DE19505960A1 (de) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Konjugat zur individuellen Dosierung von Arzneimitteln |
| US6004529A (en) * | 1997-04-11 | 1999-12-21 | Nycomed Imaging As | Chelating agents |
| AU3282300A (en) * | 1999-02-24 | 2000-09-14 | Mallinckrodt, Inc. | Molecules for the treatment and diagnosis of tumors |
| US6844425B1 (en) | 1999-02-24 | 2005-01-18 | Mallinckrodt Inc. | Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy |
| AU2003211865A1 (en) * | 2002-03-08 | 2003-09-22 | Mitsubishi Rayon Co., Ltd. | Novel fluorescent label compounds |
| KR101528013B1 (ko) * | 2009-08-31 | 2015-06-16 | 로슈 글리카트 아게 | 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체 |
| RU2454931C1 (ru) * | 2011-03-02 | 2012-07-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения и социального развития Российской Федерации | Способ диагностики распространенности опухолевого процесса у больных немелкоклеточным раком легкого |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837169A (en) * | 1981-07-01 | 1989-06-06 | Eastman Kodak Company | Polypyridine Fluorescent labels for immunoassay |
| EP0171978B1 (en) * | 1984-08-13 | 1990-11-07 | HSC Research Development Corporation | 1,10-phenanthroline-2,9-dicarboxylic acid-derivatives and their use in fluorescent immunoassay |
| DK365785A (da) * | 1984-09-17 | 1986-03-18 | Hoffmann La Roche | Metalcomplexer |
| AU8152887A (en) * | 1986-10-17 | 1988-05-06 | Cytogen Corporation | Method for preparation of protein-chelator-metal ion compositions suitable for injection |
| SE8802575D0 (sv) * | 1988-07-08 | 1988-07-08 | Wallac Oy | Terpyridine derivatives |
| GB9001245D0 (en) * | 1990-01-19 | 1990-03-21 | Salutar Inc | Compounds |
| US5367080A (en) * | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| CA2150477A1 (en) * | 1992-11-30 | 1994-06-09 | Robert Allen Snow | Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide |
| EP0691981A1 (en) * | 1993-03-10 | 1996-01-17 | The Wellcome Foundation Limited | Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides |
-
1992
- 1992-05-07 WO PCT/US1992/003858 patent/WO1993021957A1/en active IP Right Grant
- 1992-05-07 KR KR1019940703965A patent/KR950701229A/ko not_active IP Right Cessation
- 1992-05-07 AU AU23161/92A patent/AU672951B2/en not_active Expired
- 1992-05-07 BR BR9207126A patent/BR9207126A/pt not_active Application Discontinuation
- 1992-05-07 JP JP51920993A patent/JP3358141B2/ja not_active Expired - Lifetime
- 1992-05-07 AT AT92915130T patent/ATE203168T1/de not_active IP Right Cessation
- 1992-05-07 CA CA002135059A patent/CA2135059A1/en not_active Abandoned
- 1992-05-07 RU RU94046010A patent/RU2122431C1/ru active
- 1992-05-07 DE DE69231952T patent/DE69231952T2/de not_active Expired - Lifetime
- 1992-05-07 EP EP92915130A patent/EP0639083B1/en not_active Expired - Lifetime
-
1994
- 1994-11-02 NO NO944182A patent/NO944182L/no not_active Application Discontinuation
- 1994-11-04 FI FI945194A patent/FI945194A/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3358141B2 (ja) | 2002-12-16 |
| BR9207126A (pt) | 1995-08-29 |
| CA2135059A1 (en) | 1993-11-11 |
| JPH07506667A (ja) | 1995-07-20 |
| AU672951B2 (en) | 1996-10-24 |
| ATE203168T1 (de) | 2001-08-15 |
| RU2122431C1 (ru) | 1998-11-27 |
| DE69231952T2 (de) | 2002-04-04 |
| KR950701229A (ko) | 1995-03-23 |
| WO1993021957A1 (en) | 1993-11-11 |
| NO944182L (no) | 1994-12-21 |
| EP0639083A1 (en) | 1995-02-22 |
| DE69231952D1 (de) | 2001-08-23 |
| AU2316192A (en) | 1993-11-29 |
| FI945194A0 (fi) | 1994-11-04 |
| EP0639083B1 (en) | 2001-07-18 |
| NO944182D0 (no) | 1994-11-02 |
| RU94046010A (ru) | 1996-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1992008494A3 (en) | Targeting radioactive immunoreagents | |
| FI945194A0 (fi) | Kompleksointiaineita ja kohdistavia immunoreagensseja | |
| DK326785A (da) | Terapeutisk middel til paavisning og/eller behandling af tumorer og fremgangsmaade til fremstilling af et saadant middel | |
| EP0198388A3 (en) | Enterally effective biologically active peptide or protein composition, method for the production thereof, and a pharmaceutical composition containing same | |
| AU7411794A (en) | Method of tumor treatment | |
| DK307787A (da) | Hydrofobe cis-platinkomplekser samt liposomer omfattende saadanne komplekser og fremgangsmaade til fremstilling af saadanne komplekser og liposomer | |
| MX9709913A (es) | Metaloconstrucciones determinadas estructuralmente y aplicaciones. | |
| GB8328111D0 (en) | Chemical compounds | |
| FR2613365B1 (fr) | Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| NO900838D0 (no) | Fremgangsmaate til merking av proteiner. | |
| IL95327A0 (en) | Method and composition for the treatment of cardiac and of vascular hypertrophy and hyperplasia | |
| IL82629A0 (en) | Substituted 6-hydroxymethyl-carbapenem antibiotics,the preparation thereof and pharmaceutical compositions containing them | |
| ES557660A0 (es) | Un procedimiento para preparar derivados de oxotiazolidina. | |
| RU93033092A (ru) | Комплексообразующие вещества и целенаправленные радиоактивные иммунореагенты, композиции на их основе и способы лечения и диагностического исследования с применением указанных композиций | |
| ATE55389T1 (de) | 99mtc(iii)-agenzien zur myokardialen darstellung, in vivo nichtreduzierbar. | |
| IL83088A (en) | Substituted 3-isoquinolinols,their preparation and pharmaceutical compositions containing them | |
| DE3570677D1 (en) | Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation | |
| MC2397A1 (fr) | Peptide ayant une affinité pour les tumeurs et agent de diagnostic radioactif et agent thérapeutique radioactif contenant ce peptide | |
| JPS57167923A (en) | Chemorecruiting | |
| US5645814A (en) | Hexadentate complexes useful in radiographic imaging agents | |
| Terao et al. | The Different Effects of N-Ethylmaleimide and Iodoacetaraide on the Activity of Rat Liver 60S Subunits for Peptide Bond Elongation | |
| SE8801467D0 (sv) | Sett och komposition for avlegsnande av radioaktiva cesiumisotoper i biologiska system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assigment of application |
Owner name: NYCOMED IMAGING AS |